Experimental investigation of peculiarities for impact of a sorption action preparation silicon dioxide on infectious agents of cholangitis
Objective. Determination of impact of combination, consisted of 3% solution of silicon dioxide and antibacterial preparations, on bacterial cultures of S. aureus, P. aeruginosa, E. coli.
Materials and methods. Clean cultures of bacteria, kept in Collection of Microorganisms in Department of Microbiology and Immunology of Training–Scientific Centre «Іnstitute of Biology and Medicine» of Taras Shevchenko National University: S. aureus (Rosenbach, 1884), P. aeruginosa (Schröter, 1872; Migula, 1900), E. coli (Migula, 1895; Castellani і Chalmers, 1919) were applied. Action of antibacterial preparations cefoperazon, cefoperazon–sulbactam, ampicillin–sulbactam, amicacin, as well as enterosorbent 3% solution of silicon dioxide, was investigated. In the investigation the impact of antibacterial preparations and silicon dioxide together with antibacterial preparations on test–cultures of bacteria was studied, using broth and agarised medium of Muller–Hinton.
Results. The data, obtained in the investigation, trust efficacy of combined application of 3% solution of silicon dioxide, owing sorption capacity, with antibacterial preparations in reduction or elimination of subsequent growth of bacterial test–cultures of S. aureus, P. aeruginosa, E. coli. Combination of 3% solution of silicon dioxide with ampicillin–sulbactam in dilutions 64 and 32 mg/l promotes reduction of the E. coli growth on surface of agarised medium in comparison with the investigation variant without application of 3% solution of silicon dioxide. While polyresistence of P. aeruginosa revealed, 3%solution of silicon dioxide together with cefoperazon–sulbactam in concentrations 8 and 16 mg/l and ceftazidime in concentrations 8, 16, 32, 64 mg/l guarantees bactericidal effect for this microorganism. Growth of P. aeruginosa while application of 3% solution of silicon dioxide in combination with ampicillin–sulbactam in dilutions 8, 16, 32, 64 mg/l was arrested. Application of 3% solution of silicon dioxide in combination with amicacin–sulbactam 16 mg/l inhibits the S. aureus growth, what is observed, when combination of 3% solution of silicon dioxide with amicacin in dilutions 8, 16 mg/l and cefoperazon–sulbactam in dilutions 8, 16 mg/l are exploited. Growth of the microorganism do not evolve in variants of the investigation without 3% solution of silicon dioxide, as well as with him, if amikacin is applied in concentrations 64 and 32 mg/l.
Conclusion. The biliary ducts drainage in obturative jaundice of tumoral genesis and subsequent presence of drainage (internal or external) constitute the main risk factors for their colonization by multiresistant microorganisms. At the same time, the biliary ducts drainage in combination with antibioticotherapy is estimated as an urgent method for control of the infection primary focus in an acute cholangitis. Establishing of procedure for application of 3% solution of silicon dioxide in combination with certain groups of antibacterial preparations for microorganisms revealed constitute important measure for bacteriobilia prophylaxis. The further investigations conduction with wider spectrum of antibacterial preparations and 3% solution of silicon dioxide for control of clinically significant species of microorganisms is necessary and perspective.
Sokal A, Sauvanet A, Fantin B, de Lastours V. Acute cholangitis: Diagnosis and management. J Visc Surg. 2019 Dec;156(6):515–25. doi: 10.1016/j.jviscsurg.2019.05.007. Epub 2019 Jun 24. PMID: 31248783.
Müssle B, Hempel S, Kahlert C, Distler M, Weitz J, Welsch T. Prognostic Impact of Bacterobilia on Morbidity and Postoperative Management After Pancreatoduodenectomy: A Systematic Review and Meta–analysis. World J Surg. 2018 Sep;42(9):2951–2962. doi: 10.1007/s00268–018–4546–5. PMID: 29464345.
Methodical instructions "Determination of sensitivity of microorganisms to antibacterial drugs", approved: Order of the Ministry of Health of Ukraine 05.04.2007 No. 167. Available from: https://zakon.rada.gov.ua/go/v0167282–07.
Determination of sensitivity to antibacterial drugs based on IPC limit values according to EUCAST v 11.0. Available from: https://www.eucast.org/ast_of_bacteria/quality_control.
Compendium 2019 OnLine – medicines. Atoxil. Available from: https://compendium.com.ua/dec/267320/
Slowing II, Vivero–Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008 Aug 17;60(11):1278–88. doi: 10.1016/j.addr.2008.03.012. Epub 2008 Apr 10. PMID: 18514969.
Davydova YuV, Lymanska AYu. Clinical use of enterosorbents in pregnant women of high risk. Ukrainian journal of perinatology and pediatrics. , 2018;(1):36–40. Ukrainian.
Chuiko AA, editor. Medical chemistry and clinical applications of silicon dioxide. Kyiv: Naukova Dumka; 2003. 417 p. Ukrainian. ISBN 966–00–0185–1.
Pentiuk AA, Lutsyuk NB. Toxicological studies of silicis. In: Chuiko AA, editor. Medical chemistry and clinical applications of silicon dioxide. Kyiv: Naukova Dumka; 2003. 180–202 p. Ukrainian. ISBN 966–00–0185–1.
Voronin EP, Nosach LV, Pakhlov EM, Gunko VM, Chekman IS, Rudenko A V, et al. Creation of stable aqueous dispersions of nanosized silica as a sorption–detoxification agent for medical purposes. Surface. 2016;(8):267–83. Ukrainian.
Voronin EP, Chekman IS, Rudenko AV, Nosach LV, Osinnya LM. Properties of nanosized silica as a medical sorbent. Integrative anthropology. 2017; (1): 44–8.Ukrainian.
Kurdish, IR, Chuiko AA. Features of the interaction of microorganisms with highly dispersed silica. In: Chuiko AA, editor. Medical chemistry and clinical applications of silicon dioxide. Kyiv: Naukova Dumka; 2003. 153–67. Ukrainian. ISBN 966–00–0185–1.
Bondar SA, Liashenko IN, Lutsiuk NB, Trunina TI, Anfilova MR. Enterosorbent silix: characteristic and using in dermatology. Ukrainian Journal of Dermatology, Venereology, Cosmetology. 2004;(4):40–4. Ukrainian.
Lurin IA. Modern minimally invasive and endoscopic techniques in the complex treatment of choledocholithiasis. PhD(Med) [thesis]. Kyiv: NMU;2011. 19 p. Ukrainian.
This work is licensed under a Creative Commons Attribution 4.0 International License.